Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillian R Woollett

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 21, 2017
A 'Global Reference' Comparator for Biosimilar DevelopmentChristopher J Webster, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 18, 2018
Comment on "The End of Phase 3 Clinical Trials in Biosimilars Development?"Christopher J Webster, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 3, 2019
Comment on "Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?"Christopher J Webster, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 4, 2017
Erratum to: A 'Global Reference' Comparator for Biosimilar DevelopmentChristopher J Webster, Gillian R Woollett
Journal of Managed Care & Specialty Pharmacy|November 28, 2017
Pharmacovigilance of Biologics in a Multisource EnvironmentSreedhar Sagi, Hillel P Cohen, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 8, 2019
An Efficient Development Paradigm for BiosimilarsChristopher J Webster, Anny C Wong, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 18, 2021
Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized RelianceChristopher J Webster, Kelly L George, Gillian R Woollett
Clinical Pharmacology and Therapeutics|September 23, 2022
The Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right QuestionGillian R Woollett, Joseph P Park, Jihyun Han, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 5, 2023
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer's PerspectiveHillel P Cohen, Matthew Turner, Dorothy McCabe, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 13, 2022
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical OneJoseph P Park, Byoungin Jung, Hyung Ki Park, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 21, 2017
A 'Global Reference' Comparator for Biosimilar DevelopmentChristopher J Webster, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 18, 2018
Comment on "The End of Phase 3 Clinical Trials in Biosimilars Development?"Christopher J Webster, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 3, 2019
Comment on "Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?"Christopher J Webster, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 4, 2017
Erratum to: A 'Global Reference' Comparator for Biosimilar DevelopmentChristopher J Webster, Gillian R Woollett
Journal of Managed Care & Specialty Pharmacy|November 28, 2017
Pharmacovigilance of Biologics in a Multisource EnvironmentSreedhar Sagi, Hillel P Cohen, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 8, 2019
An Efficient Development Paradigm for BiosimilarsChristopher J Webster, Anny C Wong, Gillian R Woollett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 18, 2021
Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized RelianceChristopher J Webster, Kelly L George, Gillian R Woollett
Clinical Pharmacology and Therapeutics|September 23, 2022
The Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right QuestionGillian R Woollett, Joseph P Park, Jihyun Han, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 5, 2023
Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer's PerspectiveHillel P Cohen, Matthew Turner, Dorothy McCabe, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 13, 2022
Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical OneJoseph P Park, Byoungin Jung, Hyung Ki Park, et al.
Pageof 1